Patient advocacy group involvement in health technology assessments: an observational study

Plain English summary What are health technology assessments? Health technologies are medicines, devices and services used to prevent, diagnose or treat medical conditions. A Health Technology Assessment (HTA) considers the value of a health technology to help governments make fair decisions about w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ann Single, Ariana Cabrera, Simon Fifer, Jane Tsai, Jin-Young Paik, Philip Hope
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Health technology assessment Patient advocacy group Decision-making Funding Reimbursement decisions Patient and public involvement Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/955cffa5dacc411fb96b931160799aac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:955cffa5dacc411fb96b931160799aac
record_format	dspace
spelling	oai:doaj.org-article:955cffa5dacc411fb96b931160799aac2021-11-28T12:14:34ZPatient advocacy group involvement in health technology assessments: an observational study10.1186/s40900-021-00327-52056-7529https://doaj.org/article/955cffa5dacc411fb96b931160799aac2021-11-01T00:00:00Zhttps://doi.org/10.1186/s40900-021-00327-5https://doaj.org/toc/2056-7529Plain English summary What are health technology assessments? Health technologies are medicines, devices and services used to prevent, diagnose or treat medical conditions. A Health Technology Assessment (HTA) considers the value of a health technology to help governments make fair decisions about which treatments to fund or subsidise. Patients and Patient Advocacy Groups (PAGs) may be invited to provide input into this process. What did our study look at? We surveyed staff and patients from cancer PAGs in New Zealand (Aotearoa), South Korea and Taiwan to understand their experiences and expectations of involving patients in HTA. A total of 43 people completed our survey. What were the results? Overall, 20 of the 43 surveyed people (47%) were aware of the assessment process used to decide which medicines were funded in their country. (27 of these 50 people were PAG staff members.) Patients from South Korea and New Zealand were rarely included in the assessment process. Patient involvement was more commonly reported in Taiwan. The impact of input from patients on HTA was rated low by patients in both South Korea and New Zealand and average in Taiwan. A general lack of transparency, feedback on the process, and support from assessment agencies was also reported. Many of the patients surveyed wanted to see more patient involvement in the assessment processes. What is the main take-home message from this study? With improved guidance and feedback from assessment agencies, PAGs and patients believe their involvement can improve decision making on treatment funding and increase fairness through transparency.Ann SingleAriana CabreraSimon FiferJane TsaiJin-Young PaikPhilip HopeBMCarticleHealth technology assessmentPatient advocacy groupDecision-makingFundingReimbursement decisionsPatient and public involvementMedicineRMedicine (General)R5-920ENResearch Involvement and Engagement, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Health technology assessment Patient advocacy group Decision-making Funding Reimbursement decisions Patient and public involvement Medicine R Medicine (General) R5-920
spellingShingle	Health technology assessment Patient advocacy group Decision-making Funding Reimbursement decisions Patient and public involvement Medicine R Medicine (General) R5-920 Ann Single Ariana Cabrera Simon Fifer Jane Tsai Jin-Young Paik Philip Hope Patient advocacy group involvement in health technology assessments: an observational study
description	Plain English summary What are health technology assessments? Health technologies are medicines, devices and services used to prevent, diagnose or treat medical conditions. A Health Technology Assessment (HTA) considers the value of a health technology to help governments make fair decisions about which treatments to fund or subsidise. Patients and Patient Advocacy Groups (PAGs) may be invited to provide input into this process. What did our study look at? We surveyed staff and patients from cancer PAGs in New Zealand (Aotearoa), South Korea and Taiwan to understand their experiences and expectations of involving patients in HTA. A total of 43 people completed our survey. What were the results? Overall, 20 of the 43 surveyed people (47%) were aware of the assessment process used to decide which medicines were funded in their country. (27 of these 50 people were PAG staff members.) Patients from South Korea and New Zealand were rarely included in the assessment process. Patient involvement was more commonly reported in Taiwan. The impact of input from patients on HTA was rated low by patients in both South Korea and New Zealand and average in Taiwan. A general lack of transparency, feedback on the process, and support from assessment agencies was also reported. Many of the patients surveyed wanted to see more patient involvement in the assessment processes. What is the main take-home message from this study? With improved guidance and feedback from assessment agencies, PAGs and patients believe their involvement can improve decision making on treatment funding and increase fairness through transparency.
format	article
author	Ann Single Ariana Cabrera Simon Fifer Jane Tsai Jin-Young Paik Philip Hope
author_facet	Ann Single Ariana Cabrera Simon Fifer Jane Tsai Jin-Young Paik Philip Hope
author_sort	Ann Single
title	Patient advocacy group involvement in health technology assessments: an observational study
title_short	Patient advocacy group involvement in health technology assessments: an observational study
title_full	Patient advocacy group involvement in health technology assessments: an observational study
title_fullStr	Patient advocacy group involvement in health technology assessments: an observational study
title_full_unstemmed	Patient advocacy group involvement in health technology assessments: an observational study
title_sort	patient advocacy group involvement in health technology assessments: an observational study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/955cffa5dacc411fb96b931160799aac
work_keys_str_mv	AT annsingle patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy AT arianacabrera patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy AT simonfifer patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy AT janetsai patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy AT jinyoungpaik patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy AT philiphope patientadvocacygroupinvolvementinhealthtechnologyassessmentsanobservationalstudy
_version_	1718408155731329024

Patient advocacy group involvement in health technology assessments: an observational study

Ejemplares similares